Karsten Fjärstedt
Interim CEO
30+ years in operations, marketing, sales and commercialization in biotech and bioprocessing. Formerly Business Unit lead at GE Healthcare (now Cytiva), CEO of Denator and COO of Bio-Works. MSc Chemical Technology, KTH.
Cellevate AB is a Swedish biotech company and spin-out of Lund University. We supply Cellevat3d® nanofiber cell culture products to CDMOs and biopharmaceutical companies worldwide, ISO 9001:2015 certified with GMP processes in a clean room.
Interim CEO
30+ years in operations, marketing, sales and commercialization in biotech and bioprocessing. Formerly Business Unit lead at GE Healthcare (now Cytiva), CEO of Denator and COO of Bio-Works. MSc Chemical Technology, KTH.
CTO
30+ years across bioprocessing: VP R&D Bioprocess at Cytiva, VP Marketing and Product Management Fermentation Technologies at Sartorius, General Manager of Recipharm Biologics, earlier AstraZeneca and Pharmacia & Upjohn.
COO
13+ years leading R&D organizations in diagnostics, most recently VP Research and Development at Immunovia. PhD in Immunotechnology.
CFO
15+ years in finance roles across biotech, nanotech and financial services, including CFO at Opticept Technologies, Ascelia Pharma and Bioglan.
Sales & Marketing Director
20+ years in life science sales and marketing, including Immunovia, Menarini Nordics and Dako (now Agilent Technologies).
Board of Directors chaired by Uwe Gottschalk. On 23 March 2026 the board appointed Karsten Fjärstedt Interim CEO and started the search for a permanent CEO.
Cellevate AB
Lund, Sweden
Orders and product questions: sales@cellevate.com
Everything else: our contact form.

